|
| Study | Number of patients | Therapeutic approach | Clinical response | Conclusion |
|
| Schmidt-Wolf et al. [37]
| 10 (1 RCC) | Auto-CIKs transfected with IL-2 gene | 1 CR, 3 SD, 6 PD | Low toxicity of CIK cell therapy; CR in RCC patient |
| Ren et al. [31] | 66 (6 RCC) | Auto-CIKs | 40 SD, 3 PR, 11†, 12 lost | Disease stage had no influence on antitumor activity of CIK cells; number of infusion cycles and proportion of CD3+CD56+ cells important for clinical outcome |
| Olioso et al. [38] | 12 (5 RCC) | Auto-CIKs | 3 CR (1 RCC), 2 SD (both RCC), 3 withdrawn from study; response rate: 33% | No significant differences in number of infused CIK cells between responders and nonresponders; 2 of 3 CR received additional IL-2/IFN-α therapy |
| Su et al. [40] | 16 (all RCC) | Auto-CIKs | 3 CR, 1 PR, 6 SD, 6 PD; response rate: 25% | AE transient and controllable; increased production of IFN-γ and TNF-α by PBMC after CIK cell treatment |
| Liu et al. [13] | 148 (all RCC) | Arm 1: auto-CIKs
Arm 2: IL-2 + IFN-α | Arm 1: 13 CR, 26 PR, 25 SD, 10 PD; response rate: 53%
Arm 2: 5 CR, 15 PR, 25 SD, 29 PD; response rate: 27% | CIK cell treatment significantly improves prognosis of metastatic RCC; prognosis significantly better in patients who received ≥7 cycles of CIK infusions |
| Lei et al. [41] | 28 (all RCC) | Group A: auto-CIKs + IL-2 + IFN-α2b + chemo
Group B: IL-2 + IFN-α2b + chemo | January 2002–June 2006:
Group A: 15 at good health, 3†Group B: 4 at good health, 6† | Best period for infusions between 2 cycles of chemo/radiotherapy; CIK cells had a positive effect on postoperative RCC patients |
| Li et al. [42] | 12 (all RCC) | Group 1: auto-CIKs
Group 2: biotherapy | Group 1: 6 CR, 1 PR
Group 2: All PD | CIK therapy safe and effective for localized RCC patients after radical nephrectomy |
| Wang et al. [43] | 10 (all RCC) | Auto-CIKs + autologous renal tumor lysate-loaded DCs | 1 PR, 6 SD, 2 PD, 1 lost | AE tolerable; short-term efficacy on advanced RCC through induction of specific antitumor immunity |
|
